Advertisement
Research Updates

Treatment

  • Forward Look

    What’s Next? Spring 2019

    Reducing chemotherapy side effects with a ‘drug sponge.'

    by Bradley Jones

  • Keeping an Eye on Cancer

    Imaging tests for post-treatment surveillance may come with radiation exposure, financial strain, “scanxiety” and sometimes unnecessary follow-ups. Doctors and patients need to balance the risks and benefits of scanning.

    by Charlotte Huff

  • More Options for Rare Cancers

    Precision medicine and immunotherapy offer opportunities for new treatments and clinical trials to patients who previously had few, if any, options.

    by Kendall K. Morgan

  • The Patient Perspective

    Patient-reported outcomes may help shape the future of cancer care.

    by Stephen Ornes

  • Q&A

    Hope Amid the Hype

    Hematologist-oncologist David Scadden traces the history, promise and uncertainties of treatment advances in Cancerland: A Medical Memoir.

    by Marci A. Landsmann

  • First Immunotherapy Approved for Breast Cancer

    Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

    by Anna Azvolinsky

  • Holding Off on Treatment

    Patients diagnosed with low-risk prostate cancer are increasingly opting against immediate surgery or radiation in favor of regularly monitoring their disease.

    by Jon Kelvey

  • Making Clinical Trials More Inclusive

    Broadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.

    by Ashley P. Taylor

  • What Do Clinical Trial Endpoints Really Measure?

    A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.

    by Jon Kelvey

  • Treating Breast Cancer in Men

    Hormone therapy may lengthen life in men with hormone-related breast cancer, but this treatment is prescribed less frequently for men than for women.

    by Marilyn Fenichel